ACKNOWLEDGMENTS
We acknowledge Juan Manuel Carreno Quiroz, Florian Krammer, and Roshan Ramanathan for contributions to the study design and Kalina Wong for statistical programming and data analysis.Protocol: Emergent is receiving funding from the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, under Other Transaction number W911QY-20-9-0013, for the development of COVID-HIGIV, a countermeasure to SARS-CoV-2. The U.S. government is authorized to reproduce and distribute reprints for governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. government.Supplemental material is available online only.
Supplemental material. Download 